Pharmacovigilance area of interest | ||||||
---|---|---|---|---|---|---|
Activity type | Adverse events | Counterfeit drugs | Drug quality assurance | PV NOS | NA | Total |
Behaviour change communication | 3 (75.0) | 1 (25.0) | 4 (2.1) | |||
Improve regulatory system | 5 (19.2) | 12 (46.2) | 9 (34.6) | 26 (13.8) | ||
Improving supply chain | 5 (45.4) | 6 (54.5) | 11 (5.9) | |||
Laboratory supplies and training | 4 (18.2) | 17 (77.3) | 1 (4.5) | 22 (11.7) | ||
Operations research | 2 (100) | 2 (1.1) | ||||
Pharmacovigilance NOS | 2 (8.7) | 5 (21.7) | 15 (65.2) | 1 (4.3) | 23 (12.2) | |
Surveillance | 2 (9.5) | 5 (23.8) | 13 (61.9) | 1 (4.8) | 21 (11.2) | |
Training/capacity building | 5 (55.6) | 4 (44.4) | 9 (4.8) | |||
Surveillance-not funded | 1 (100) | 1 (0.5) | ||||
Pharmacovigilance NOS-unfunded | 6 (100) | 6 (3.2) | ||||
Context onlya | 35 (100) | 35 (18.6) | ||||
Historical activityb | 6 (13.3) | 26 (57.8) | 12 (26.7) | 1 (3.8) | 45 (23.9) | |
Total | 7 (3.7) | 22 (11.7) | 94 (50.0) | 35 (18.6) | 36 (19.1) | 188 (100.0) |